Ruth M. Nabisere - Publications

Clinical predictors of 3-month isoniazid rifapentine (3HP)-related adverse drug reactions (ADR) during tuberculosis preventive therapy (PAnDoRA-3HP study): an observational study protocol.

Journal: BMJ open

Published: December 31, 2024

Dolutegravir pharmacokinetics in Ugandan patients with TB and HIV receiving standard- versus high-dose rifampicin.

Journal: Antimicrobial agents and chemotherapy

Published: October 18, 2023

Unexpectedly low drug exposures among Ugandan patients with TB and HIV receiving high-dose rifampicin.

Journal: Antimicrobial agents and chemotherapy

Published: October 18, 2023

Decreased Dolutegravir and Efavirenz Concentrations With Preserved Virological Suppression in Patients With Tuberculosis and Human Immunodeficiency Virus Receiving High-Dose Rifampicin.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Published: April 19, 2022

Community Health Workers Improve HIV Disclosure Among HIV-Affected Sexual Partners in Rural Uganda: A Quasi-Experimental Study.

Journal: Global health, science and practice

Published: September 10, 2021

Implementation of TB preventive therapy in Uganda: effect of an intervention on completion rates.

Journal: The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease

Published: January 01, 2021

Pharmacokinetics, SAfety/tolerability, and EFficacy of high-dose RIFampicin in tuberculosis-HIV co-infected patients on efavirenz- or dolutegravir-based antiretroviral therapy: study protocol for an open-label, phase II clinical trial (SAEFRIF).

Journal: Trials

Published: November 11, 2019

Knowledge, Attitudes, and Perceived Risks Related to Diabetes Mellitus Among University Students in Uganda: A Cross-Sectional Study.

Journal: The East African health research journal

Published: December 19, 2017